Ovarian cancer: markers of response.

摘要: Objectives: Despite improved knowledge regarding the etiology of ovarian cancer, as well application aggressive surgery and chemotherapy, there has been only a modest change in mortality statistics over last 30 years. Given these results evolution targeted therapies, is an increasing need for prognostic predictive factors to stratify patients individualized care. Many laboratories have also investigated specific individual biomarkers correlating them with clinicopathologic characteristics. Unfortunately, vast majorities not proved clinically valuable. In this article, we review published genomic signatures including data generated our laboratory their relevance. Methods: Multiple expression profiling articles were selected discussion. Genomic studies separated from those dichotomized survival unsupervised analysis identify discreet subsets tumors that activated pathways. Results: The identification common. Few validated. profiles obtained distinguish short- long-term survivors. relevance large number within extremes remains unclear. Unsupervised clustering cancers identified potential reflect different clinical behavior. These will require numbers independent samples validation. Another approach genes correlate patient continuous variable. are then placed into biologic context using pathway analysis. pathways provide therapeutic targets, whose express targets may be most effectively treated by inhibitors pathway. Conclusions: There major cancer. With development new technologies, opportunity gene can used according ultimate response chemotherapy. Large sets robust statistical techniques required fully exploit approach.